:max_bytes(150000):strip_icc():focal(717x224:719x226)/kelly-ripa-mark-consuelos-live-2-080525-9e98d41d17134c0c9b0dac66dac4cc7a.jpg)
Novo Nordisk has struck a $2.1B licensing deal with Omeros for global rights to zaltenibart, a first-in-class MASP-3 inhibitor for rare diseases.
October 15, 2025
Source:
Getty Images
Major Acquisition Targets Rare Diseases
Novo Nordisk has announced a sweeping $2.1 billion licensing deal with Omeros Corporation for global rights to zaltenibart (OMS906) (Fierce Pharma). The deal includes $340 million in upfront and near-term milestone payments.
Why Zaltenibart?
Zaltenibart is a first-in-class MASP-3 inhibitor targeting the complement system, crucial in immune response (Evaluate Vantage).
The therapy intends to address rare blood and kidney disorders with limited existing options.
Novo Nordisk gains exclusive rights to develop and commercialize zaltenibart worldwide.
Keep up with the story. Subscribe to the PR+ free daily newsletter
Source:
Omeros Corporation
Complement System: A Growing Focus
The complement system is an immune pathway central to several rare diseases. Targeting MASP-3 aims to regulate abnormal immune responses linked to conditions like atypical hemolytic uremic syndrome (NCBI).
Therapeutic Innovation
Current drugs like eculizumab inhibit other complement proteins, but zaltenibart’s MASP-3 focus marks a unique approach.
Experts highlight high unmet medical need in this field (Pharmaceutical Technology).
Industry Momentum
Rare disease drug development is attracting increased investment, with strategic deals emphasizing new immunology advances (Endpoints News).
Read More
Source:
Shutterstock
Share this news:
